Hepatitis C Articles (HCV)
Back
	Genotype 3 - prevalence, treatment       HCV Genotype 3 Treatment: Daclatasvir+Sofosbuvir, Sofosbuvitr+Peg/Rbv / EASL-Abbvie/Gilead/J&J/Merck/BMS/Achillion/African-Americans/New Drugs - (06/15/15)   High Efficacy of Treatment With Sofosbuvir + GS-5816 ± Ribavirin for 12 Weeks in Treatment-Experienced Patients With Genotype 1 or 3 HCV Infection - (11/12/14)   High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection - (11/12/14)   ELECTRON-2 - Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients, and GT 1 Patients With Prior Sofosbuvir Experience - (04/11/14)   Global Distribution & Prevalence of HCV Genotypes (GT3) - (06/15/15)   HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis - (06/15/15)   Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study....genotype 3 was found in 20.8% - (06/15/15)   Genotype 3 Numbers in USA - (06/15/15)   Genotypes, Genotype 3 (GT3) in VA, Global - (06/15/15)   HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCV - (06/15/15)   GT3 Progress quickly - HCV/HIV Coinfected Patients & Switching ARTs - GT3 Daclatasvir/SOF 24 Weeks Model 95% SVR - (06/15/15)           View Older Articles   Back to Top   www.natap.org